NCI SBIR Development Center Program with FDA CARE – Connecting Awardees with Regulatory Experts

Application Form for NCI Small Businesses

Thank you for your interest in the CARE Program. Please complete one application form per applicable project. To be eligible to participate, your small business:

Received a Phase I or II SBIR/STTR award from the National Cancer Institute (NCI) in fiscal year 2020 or later Has a technology that falls under the regulatory authority of the U.S. Food and Drug Administration (FDA) Has not met/discussed this product with FDA or participated in the CARE Program previously for this product Has visited this website to answer basic regulatory questions <a href="https://sbir.cancer.gov/resources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdaresources/fdar

I have reviewed the eligibility requirements listed above and meet all the criteria.

Please note the text space limits within the application fields. All forms must be submitted by March 11, 2022. Email completed application form to NCIsbirEvents@mail.nih.gov.

Award Information NCI SBIR Award Number for this product/technology: NCI SBIR Program Director:

Company Information

Company name:

Contact person for this application:

Title/Role:

Email:

Phone:

Indicate the technology area(s) that describe the SBIR/STTR-funded technology (select all that apply):

Small molecule Surgical or ablative device Imaging agent Biologics/vaccine Hospital device Imaging device

Cell/gene therapy Drug delivery device Bioinformatics/health IT/digital health

In vitro diagnostic

Indicate the development stage of the SBIR/STTR-funded technology:

Early stage (in vitro or untested prototype) Ready to commercialize Ongoing (in vivo testing or refining an early design) Commercial product

Testing in a clinical setting

Technology name (please provide a short, ten words or fewer, description of your technology):

What is the unmet medical need that your technology addresses? How does your technology solve th problem? Limit your response to 500 characters maximum, including spaces.	e
Does your potential technology fall under FDA's regulatory authority? Center for Biologics Evaluation and Research (CBER) Center for Drug Evaluation and Research (CDER) Center for Devices and Radiological Health (CDRH) Unsure	
Has your company met with FDA previously to discuss the regulatory strategy for this technology? Yes No Unsure If yes, please provide approximate date and type of meeting.	
Has your company attended any educational workshops, webinars, or other events hosted by FDA in the past 2 years? Yes No Unsure If yes, please list the name(s) and approximate date(s).	in
Does your company currently have access to a regulatory consultant? Yes No Unsure If yes, have you discussed your questions on page 4 with the consultant?	

Yes No Unsure Are you familiar with CBER's Manufacturers Assistance and Technical Training Branch (Manufacturers Assistance and Technical Training Branch (MATTB) | FDA)? Yes No Unsure Not applicable to my technology Are you familiar with CDER's Oncology Regulatory Expertise and Early Guidance Initiative (https://www.fda.gov/about-fda/oncology-center-excellence/oncology-regulatory-expertise-and-earlyguidance-oreeg)? Yes No Unsure Not applicable to my technology

Are you familiar with any of FDA's industry education websites (i.e., CBER/CDER/CDRH Learn)?

Are you familiar with CDRH's Early Payor Feedback Program (https://www.fda.gov/about-fda/cdrh-innovation/payor-communication-task-force/#2)?

Yes

No

Unsure

Not applicable to my technology

Are you familiar with CDRH's Regulatory Science Tools Catalog to help assess new medical devices (https://www.fda.gov/medical-devices/science-and-research-medical-devices/catalog-regulatory-science-tools-help-assess-new-medical-devices)?

Yes

No

Unsure

Not applicable to my technology

PLEASE USE THIS WEBSITE TO FIND BASIC INFORMATION BEFORE YOU SUBMIT YOUR QUESTIONS TO THE FDA: https://sbir.cancer.gov/resources/fdaresources

Please state up to five regulatory questions you have for FDA. Please number each question separately (i.e., do not include multi-part questions).

1.

2.

3.

4.

5.

Please include relevant background information for each question on the previous page. This will allow FDA to provide a more informed response to your questions.

The CARE Program is intended to provide small businesses with product type information from FDA. This program does not replace any formal or informal meetings encouraged or required by FDA. Information provided as part of this program will not be used by FDA for any preliminary or future decision-making regarding the technology.

1.

2.

3.

4.

5.